FTC urges top PBMs to outline effects on drug pricing, pharmacies

The FTC is requesting large, vertically-integrated players in the pharmacy benefit management industry share insights on their influence over drug pricing and access. 

Advertisement

The request for information follows a previous public inquiry on PBMs, which revealed that independent pharmacies found contracts with PBMs to be confusing and predatory. 

The request targets payers with vertically-integrated PBMs, including UnitedHealth Group’s OptumRx, Cigna’s Express Scripts and CVS Health’s Caremark. 

The public comment period extends through April 25.

At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 17–19 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.

Advertisement

Next Up in Policy Updates

Advertisement

Comments are closed.